---
title: Potential future direction of measurable residual disease evaluation in multiple
  myeloma
date: '2023-07-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37471603/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230720211416&v=2.17.9.post6+86293ac
source: Blood
description: Multiple myeloma remains an incurable disease plagued by high relapse
  rates. Deeper and more sustainable responses however, have been consistently shown
  to improve outcome and could eventually pave the way to achieving cure. Our understanding
  of disease response has surpassed complete response (CR) as the current definitions
  are suboptimal, and treatment goal should aim even beyond stringent CR, towards
  molecular and flow CR, i.e., measurable residual disease (MRD). It has been more
  than ...
disable_comments: true
---
Multiple myeloma remains an incurable disease plagued by high relapse rates. Deeper and more sustainable responses however, have been consistently shown to improve outcome and could eventually pave the way to achieving cure. Our understanding of disease response has surpassed complete response (CR) as the current definitions are suboptimal, and treatment goal should aim even beyond stringent CR, towards molecular and flow CR, i.e., measurable residual disease (MRD). It has been more than ...